RESOURCES
Touchlight Resources: The dbDNA™ Knowledge Centre
MegaBulb DNA: Enabling better non-viral gene therapy with mbDNA™ – a cell-free circular ssDNA
MegaBulb DNA: Enabling better non-viral gene therapy with mbDNA – a cell-free circular ssDNA ...
Nanopore sequencing purity assessment of AAV genomes produced using dbDNA™
Touchlight’s dbDNA™ enables fast, scalable GMP-grade AAV production with fewer impurities and no bacterial sequences, confirmed by nanopore sequencing ...
dbDNA™: The Future of AAV Production
dbDNA™: The Future of AAV Production Recombinant adeno-associated virus (AAV) is one of the most promising delivery vehicles for genetic ...
From Lab to Clinic: How z- dbDNA is Changing RNA Cell Therapy
From Lab to Clinic: How z- dbDNA™ is Changing RNA Cell Therapy RNA is revolutionising cell therapy. Whether it's encoding ...
Enabling better non-viral gene therapy with mbDNA™ – a circular ssDNA molecule
mbDNA™ is a groundbreaking non-viral gene-editing technology with a unique circular single-stranded DNA design, engineered for high HDR efficiency and ...
CRISPR HDR Breakthrough with mbDNA™: ssDNA Template Boosts Cell Viability & Scalability
CRISPR HDR Breakthrough with mbDNA™: ssDNA Template Boosts Cell Viability & Scalability CRISPR has transformed our ability to edit genomes, ...
mbDNA™: The Smarter DNA for Non-Viral Gene Editing
mbDNA™ is a synthetic, circular single-stranded DNA (ssDNA) vector engineered to overcome the limitations of both viral and non-viral gene-editing ...
mbDNA™: Setting a new standard in gene editing with a single-stranded circular DNA platform
mbDNA™ (megabulb DNA) is a groundbreaking circular single-stranded DNA platform designed to revolutionise gene editing. Engineered for high stability, low ...
Inside Touchlight’s DNA Manufacturing Facility
This video introduces Touchlight’s state-of-the-art DNA manufacturing facility, located in the historic Morelands Waterworks in Hampton. Once a vital site ...
Technology Talk – An introduction to dbDNA™ and mbDNA™
In this webinar, Touchlight’s Elena Stoyanova, PhD introduces the company’s innovative DNA manufacturing technologies, focusing on their proprietary dbDNA™ (Doggybone ...
Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model
Learn how doggybone DNA (dbDNA™) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune ...
Optimizing a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen
This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase ...
Enzymatically amplified linear dbDNA™ as a rapid and scalable solution to industrial lentiviral vector manufacturing
This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector ...
Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as ...
Novel synthetic plasmid and DoggyboneTM DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are ...
Cell-Free DNA for AAV production
Replacing plasmid DNA with enzymatically produced DNA in your AAV production eliminates many issues around complex or unstable sequences, purity, ...
Doggybone™ DNA: an advanced platform for AAV production
Recombinant AAV is a powerful vector for gene delivery—but its full potential is held back by the limitations of plasmid ...
Leveraging Synthetic DNA in AAV Manufacturing to Increase Efficiency
Discover how synthetic, backbone-free DNA offers a safer, scalable alternative to traditional plasmid DNA for AAV production, addressing key challenges ...
CAR T Cell Generation by piggyBac Transposition from Linear dbDNA Vectors Requires Transposon DNA-Flanking Regions
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are ...
Improved CRISPR Gene Editing with dbDNA as a Knock-In Template
Touchlight’s robust and rapidly scalable manufacturing technology, offers a reliable and effective alternative to pDNA as a knock-in template for ...
Addressing pDNA challenges in large-scale manufacturing of rAAV and rLV
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) ...
dbDNA as a rapid and scalable solution to industrial lentiviral vector manufacturing
Here, we demonstrate that dbDNATM can be optimised for the manufacture of high titre LVV ...
SARS-CoV-2 Doggybone DNA vaccine produces cross-variant veutralising antibodies and is protective in a COVID-19 animal model
The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection ...
Safe and Stable Generation of Human iPSCs Using dbDNA™ Vectors
Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on ...
Accelerating RNA manufacturing with GMP-compliant dbDNA technologies
Touchlight’s dbDNA (doggybone DNA) is a novel and disruptive advancement in DNA manufacturing technology, designed to overcome the limitations of ...
Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with z- dbDNA
LISA CAPRONI, PH.D. As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often ...
Synthetic dbDNA™ Drives a Sustainable Future for Genetic Medicines
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid ...
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy ...
MegaBulb DNA: A Non-Viral ssDNA Breakthrough Revolutionising Gene Editing
ELENA STOYANOVA, PH.D. & TOM ADIE, PH.D. Touchlight is at the forefront of innovation in gene editing technology with our ...
Revolutionising the Genetic Medicine Landscape with Enzymatic DNA
Touchlight is pioneering the next generation of DNA manufacturing with our transformative dbDNA™ technology. The enzymatic DNA manufacturing platform sets ...
Transforming the Economics of AAV Production whilst Optimising Quality Using dbDNA™
TOM MERRITT, PH.D. Traditional methods for the production of adeno-associated viral (AAV) vectors — crucial components in gene therapies — ...
Enzymatic DNA vs plasmid DNA
Enzymatic DNA vs plasmid DNA Published: 27 January 2025 Dr Tommy Duncan Is enzymatically produced DNA an alternative to plasmid ...
Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications
Elena Stoyanova, Hyatt Balke-Want, Marianaa Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, ...
Optimizing Personalized Cancer Immunotherapy Manufacturing Using Enzymatic DNA
DR LISA CAPRONI & DR PIERRE MARSCHALL On-demand webinar (Recorded December 5, 2023)Nucleic acid vaccination is emerging as a potentially ...
MegaBulb DNA (mbDNA) – a novel circular ssDNA CRISPR template for gene editing
Download the poster here ...
Nature Gene Therapy – Enzymatically amplified linear dbDNA as a rapid and scalable solution to lentiviral vector manufacturing
SARAH MOORE & MARIA BARREIRA With contribution by Helen Horton and Claire KerridgeTraditional bacterial fermentation techniques used to manufacture plasmid ...
